Life Sciences Innovative Manufacturing Fund (LSIMF)
Department for Science, Innovation and Technology (DSIT) · United Kingdom
The Life Sciences Innovative Manufacturing Fund (LSIMF) provides capital grants to support investment in the manufacture of medicines, diagnostics, and medical technologies, strengthening UK health resilience and accelerating access to life sciences products.
Summary
Deadline
30 Mar 2030
Complexity
Medium
Time to apply
20-60 hours
Updated
9 Jun 2026
The Life Sciences Innovative Manufacturing Fund (LSIMF) provides capital grants to support investment in the manufacture of medicines, diagnostics, and medical technologies, strengthening UK health resilience and accelerating access to life sciences products.
Eligibility
Applicant types
Business
Business size
SME, Large
Industries
Life sciences, pharmaceuticals, medical diagnostics, medical technology
Match funding
Needs verification
Requirements
UK-registered private sector businesses including product developers, contract development manufacturing organisations, and generics manufacturers Verification Required — LSIMF capital grant for life sciences manufacturing; see Find a Grant guidance. To increase UK health resilience and create economic growth through investment in life sciences manufacturing capacity and capability
Eligible applicants
UK-registered private sector businesses including product developers, contract development manufacturing organisations, and generics manufacturers
Funding and scope
Benefit amount
£520,000,000
Total fund available
£520,000,000
Funding intensity
Grant typically covers 10–20% of project costs, up to 25% maximum.
Payment type
Reimbursement
Eligible scope
To increase UK health resilience and create economic growth through investment in life sciences manufacturing capacity and capability
Eligible expenses
Not specified
Ineligible costs
- Projects related to veterinary medicine, herbal medicines, nutritional supplements, raw ingredients, standalone consumables, and secondary packaging
Application and risks
Application platform
Expression of Interest (EOI) followed by application process via LSIMF portal
Competitiveness
Competitive Selection
Decision timeline
Not specified
Assessment process
Multi-stage process including EOI screening, health resilience assessment, panel interview, financial and economic assessment, and due diligence
Application sections
Not specified
Application components
- Expression of Interest
- application forms
- financial and project documentation
- panel interview
- due diligence documentation
Timeline and partners
Opening date
30 Oct 2024
Project duration
Verification Required
Project start
Not specified
Project end
Not specified
Co-funders
Not specified
Collaboration rules
- Verification Required
Consortium requirements
- Verification Required
Additional guidance
[{"label":"Key Organisational Requirements","value":"Must be a UK-registered company or establishment; must provide audited accounts or evidence of funding; must demonstrate manufacturing capability or product development track record"},{"label":"Funding Structure","value":"Grants typically cover 10–20% of project costs (maximum 25%); minimum project size £8 million"},{"label":"important notes","value":"Applications are assessed in quarterly rounds; funding subject to subsidy control rules; projects must be UK-based and capital investment focused; annual review of scheme may change criteria and timelines"}]
Quick facts
- Status
- Open
- Deadline
- 30 Mar 2030
- Funding amount
- £520,000,000
- Funding band
- Large (£5M+)
- Funding type
- Capital grant
- Payment type
- Reimbursement
- Audience
- Business
- Industry
- Life sciences, pharmaceuticals, medical diagnostics, medical technology
- Last updated
- 9 Jun 2026
- Published
- 30 Oct 2024